• Peng Sun, Dongmei Yan, Bin Li, Liping Tang, Lingxia Xu, and Fei Wang.
• The Affiliated Hospital of Jiangxi University of Chinese Medicine.
• Medicine (Baltimore). 2021 Jun 18; 100 (24): e26370e26370.

BackgroundCoronavirus disease 2019 (COVID-19) is an epidemic infectious disease resulted from 2019 novel coronavirus (2019-nCoV). Up till now, COVID-19 has swept globally. Currently, due to many high-profiled benefits, clinical studies on Toujie Quwen granule (TJQW) have been increasing. The aim of the study is to assess the efficacy and safety of TJQW used with conventional western therapy for COVID-19.MethodsRelevant randomized controlled trials (RCTs) were searched in Chinese and English databases, and the search time is January 2020 to May 2021. English databases include PubMed, Embase, Web of Science, and the Cochrane Library. Chinese databases include CNKI, WF, VIP, and CBM. The international clinical trial registration platform and the Chinese clinical trial registration platform of controlled trials will be searched by us from January 2020 to May 2021. According to the inclusion and exclusion criteria, screening literature, extraction data will be conducted by 2 researchers independently. Statistical analysis will be conducted using the RevMan 5.3.5 software. After screening the literature based on the inclusion and exclusion criteria, The Recommendation, Assessment, Development, and Evaluation (GRADE) system will be used to evaluate the quality of each result.ResultsThis study will provide the evidence for TJQW to be used with conventional western therapy for COVID-19.ConclusionThe efficacy and safety of TJQW used with conventional western therapy for COVID-19 will be assessed.Inplasy Registration NumberINPLASY202150038.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

17 keywords...

hide…